<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>佰傲谷BioValley | wechat-feeds</title><link>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</link><description>佰傲谷致力于打造一个垂直于生物制品领域的第三方平台。为生物制药企业提供品牌推广、技术咨询、项目交易、企业合作、人才培养等服务。为生物制药行业从业人员提供沟通交流、会议培训、工作求职、个人展示平台。</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 04 Feb 2021 13:18:10 +0800</pubDate><image><url>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</url><title>佰傲谷BioValley | wechat-feeds</title><link>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>安进2020财报：总收入254亿美元！5款药物研发亮红灯</title><link>https://mp.weixin.qq.com/s/4267A7wOrtfsRvwhyCqoGw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpYJvlTDRe08hISahbjxGDoNSNJCcBkk7Yaia1AAm3XiaVmav0vJVVzuKrzgHqAVVhGiblJvQAjW81kZQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>生物仿制药的威胁仍然存在]]></content:encoded><pubDate>Thu, 04 Feb 2021 12:01:23 +0800</pubDate></item><item><title>GSK加倍下注mRNA技术，1.8亿美元寻找下一代COVID-19疫苗</title><link>https://mp.weixin.qq.com/s/f30jeq0ZNMRiFxbSkVlGig</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpYJvlTDRe08hISahbjxGDoNLXqZxoFcXDsM4VBcaoed5poo95eeQSrhTkyHxGEnATxhljhXqsAytA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>“无人问津”到“门庭若市”]]></content:encoded><pubDate>Thu, 04 Feb 2021 12:01:23 +0800</pubDate></item><item><title>多地上市成药企潮流，贝达药业港股上市申请获证监会受理</title><link>https://mp.weixin.qq.com/s/iiSdBWg11klpHn-dTFgVfg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpYJvlTDRe08hISahbjxGDoNLS14xdjTs46S5Y029R1hJ63WINgZLhmJT01dFRfDicicDKSeuWhEMHUg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>佰傲谷快讯]]></content:encoded><pubDate>Thu, 04 Feb 2021 12:01:23 +0800</pubDate></item><item><title>科兴新冠灭活疫苗附条件上市申请获国家药监局受理</title><link>https://mp.weixin.qq.com/s/BhuHJTB9MQy-7vO29miFMQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpYJvlTDRe08hISahbjxGDoNiaaxXZ5J4kOqVxiaopfibK6Fj4JUicQGBm22ISvW4WVmB9DRfQhZIINtoQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>佰傲谷分享]]></content:encoded><pubDate>Thu, 04 Feb 2021 12:01:23 +0800</pubDate></item><item><title>股价被腰斩，Immunovant公司宣布终止抗FcRn抗体临床研究</title><link>https://mp.weixin.qq.com/s/eVRCiFICMklNHaMn3-axQQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpY6fMGLXiafBiaoYnicYxLQJ8f3iafSvOstEOKAqcf9r47NVWI0EbatiatBNI1s7IVfxlrGbl86nGIk2tQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>抗FcRn 抗体：自身免疫性疾病的革命性疗法]]></content:encoded><pubDate>Wed, 03 Feb 2021 12:24:56 +0800</pubDate></item><item><title>信达生物PD-1单抗在华获批NSCLC领域适应症</title><link>https://mp.weixin.qq.com/s/jTTMbmpgneqtpKJuanvpmg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpY6fMGLXiafBiaoYnicYxLQJ8fwVvMBLePtpooCIYKgX6OVh6kibrcKibqQjkSiauic19jBdc8dTzQ62UKBw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>今日（2021年2月2日），国家药品监督管理局（NMPA）药品批准证明文件通知显示，信达生物的信迪利单抗注射]]></content:encoded><pubDate>Wed, 03 Feb 2021 12:24:56 +0800</pubDate></item><item><title>高瓴26亿入股诺诚健华！誓要集齐中国生物医药“七龙珠”</title><link>https://mp.weixin.qq.com/s/ma07O4niBq7htv7OzV8KlA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpY6fMGLXiafBiaoYnicYxLQJ8fDdVC3nR7cmtJHbrcBz9jb3kI0qOkeJ6PtYiaReZC2qRQqz1pS1QibXGA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>佰傲谷独家]]></content:encoded><pubDate>Wed, 03 Feb 2021 12:24:56 +0800</pubDate></item><item><title>靶向IL-6疗法的十年</title><link>https://mp.weixin.qq.com/s/xLxIxO3w1JUlyxRHwBmZ2Q</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpYKMbTs0aHYE88PiaQIicf8zANrtOyIotqpXRibAOkF0ylVE3VkrDyx35soHwqgftHc77f3cHJVD6hIw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>十年一剑，IL-6疗法的前世今生。]]></content:encoded><pubDate>Tue, 02 Feb 2021 16:46:42 +0800</pubDate></item><item><title>股价涨幅超7%，君实生物与Coherus达成70亿元合作</title><link>https://mp.weixin.qq.com/s/QAXOSotrG2ecK_sOdv22Ew</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpYKMbTs0aHYE88PiaQIicf8zAo6lydQ5TicEVdV69zr0NXzF3lWKNPvQR9HTpuovABewQjHTvKJju3Ig/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>未来，本土Biotech的创新药会有更多的机会出海。]]></content:encoded><pubDate>Tue, 02 Feb 2021 16:46:42 +0800</pubDate></item><item><title>转战新阵地，拓宽适应症：新冠背景下的干扰素市场分析</title><link>https://mp.weixin.qq.com/s/baS2n5hhe7O1-_8VsC_tyw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpZrbic47GiaVGf5ickiaQucTbKKZEXko2E7QwNOhoJ6l8bBhRibAyedESgtUnMWrZ9jicib37OcYbiclbrGcg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>未来可期]]></content:encoded><pubDate>Mon, 01 Feb 2021 12:41:34 +0800</pubDate></item><item><title>股价大涨19%，康希诺腺病毒载体疫苗成功达到预设的主要安全性及有效性标准</title><link>https://mp.weixin.qq.com/s/5J1xs7qBbbxlp_YY5Yd17w</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpaLzbpicxSGBQeMTQk52drmPL9LpDCibztjIF1PEogibkKPs7peiaRFtVLGgclToE8N6Z23NQfGzHJG7w/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>愿早日上市]]></content:encoded><pubDate>Mon, 01 Feb 2021 12:41:34 +0800</pubDate></item><item><title>“总体保护效力66%”，首个单剂接种新冠疫苗III期中期分析公布，来自强生</title><link>https://mp.weixin.qq.com/s/crXEElCR73qWuyTkhylmSg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpaLzbpicxSGBQeMTQk52drmPR63lLd03IIhygxCiaHZBqK2AHGk7FJBJyBh5LPXZBS8LJsNiaXVH2g4g/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>美国72%，拉丁美洲66%，南非57%。]]></content:encoded><pubDate>Mon, 01 Feb 2021 12:41:34 +0800</pubDate></item><item><title>靶点药讯46|纵览全球药物靶点动态</title><link>https://mp.weixin.qq.com/s/-oFIFSOzZvfItaMicvjBjA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpZrbic47GiaVGf5ickiaQucTbKKOEGWKAEgMtSmibLb59K7p2kPqEPHyzH5mPAhvCke1tTPkTMh4nA9OGA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>德琪医药、百济神州、艾伯维、和黄医药、拜耳......]]></content:encoded><pubDate>Sun, 31 Jan 2021 11:57:56 +0800</pubDate></item><item><title>Nat Immunol:成人和儿童新冠抗体应答不同</title><link>https://mp.weixin.qq.com/s/DaoatrP6Et5MdWgi8LSyVQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpbxfsZ7CGp8pmKTibv4IDh2Z7sBc2ClqpicHUNmYMRF3UbUcvUDoH2WpjaPqp4VsvQWNcI6I5lia3qCQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>]]></content:encoded><pubDate>Sun, 31 Jan 2021 11:57:56 +0800</pubDate></item><item><title>恒瑞申报第四款ADC药物，“魔法子弹”的竞争早已开始</title><link>https://mp.weixin.qq.com/s/bb2fX0WsGLaYPRXJ924Efg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpZ3L9WFriaibyFv30JfrGf7uSey6BTsXQXS87zlN2xabf9r054kzB8jAmpeHLib7ZsZJiaicDXaYnmiaPZg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>谁能分得大蛋糕？]]></content:encoded><pubDate>Sat, 30 Jan 2021 11:30:57 +0800</pubDate></item><item><title>或将实现“三级跳”，百济神州科创板上市申请获受理</title><link>https://mp.weixin.qq.com/s/6mLasvoDioZsWmbaNZgETw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpZ3L9WFriaibyFv30JfrGf7uSz0nt2EvgJ5DmMNfrvexGAicibuY2wz4ANN31EVJVx4I2MJam79UHZMibg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>百济神州的三级跳]]></content:encoded><pubDate>Sat, 30 Jan 2021 11:30:57 +0800</pubDate></item><item><title>“仅49.4%”，首个新冠南非变异毒株疫苗保护效力公布，来自Novavax</title><link>https://mp.weixin.qq.com/s/0O-SxM_3YWDhN0vtwqfyng</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpZrbic47GiaVGf5ickiaQucTbKK7zibdsMPx7w63ibD2S46vkupwhgUCprxibxTjtrmS5TOeC3KUueRwOg3Q/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>对原始毒株高度有效的新冠疫苗在面对南非变异毒株时效果下降明显。]]></content:encoded><pubDate>Fri, 29 Jan 2021 11:48:30 +0800</pubDate></item><item><title>风波叒起，辉瑞JAK抑制剂Ⅳ期临床研究失败</title><link>https://mp.weixin.qq.com/s/KdJA4L2e8fCORdnsUOazRg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpZrbic47GiaVGf5ickiaQucTbKKx01q6KrxBeFn4PhOichibibibgA76vQzuTRVMuTmDRMLTUf76yLuSKfiafg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>]]></content:encoded><pubDate>Fri, 29 Jan 2021 11:48:30 +0800</pubDate></item><item><title>一天内4项BD交易，包括礼来、默克等巨头</title><link>https://mp.weixin.qq.com/s/zB_sV_hihslr7WaZM5VLdA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpZrbic47GiaVGf5ickiaQucTbKKWdibZBYdia2nnbA1n2icL9PLzSibOKKAWX17fDFI9IicxYTUzN22q4jIWgw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>一天，四项BD]]></content:encoded><pubDate>Fri, 29 Jan 2021 11:48:30 +0800</pubDate></item><item><title>偶联抗体好难好费时间？用了这款“傻瓜式”神器，3步解决抗体偶联！</title><link>https://mp.weixin.qq.com/s/z9XQSjTHvHntI8swHGBRtg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpazPS1L4EwkdoGWLEqdNVlEe7X18U2diaic31btjJh0EPZPWdxS9ChC4defU9icV7wYMTDKpicwLNg92g/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>直标抗体应用虽越来越多也越来越受重视，可选择范围依然那么有限。有合适的抗体，却没有想要的标记，怎么办？定制太漫长，只争朝夕。]]></content:encoded><pubDate>Thu, 28 Jan 2021 12:15:58 +0800</pubDate></item></channel></rss>